Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Yearly Archives: 2009

Aegis Therapeutics and Roche Enter into a License Agreement for ProTek® Stabilization

SAN DIEGO, CA December 1, 2009/MarketWire/– Aegis Therapeutics LLC (Aegis) announced today that they have signed a License Agreement providing Roche access to Aegis’ proprietary ProTek® stabilization technology. The ProTek® technology covers the use of specific excipients as stabilizers in certain manufacturing processes and formulations of protein-based therapeutics. Under the terms of the agreement, Aegis […]

Aegis Therapeutics to Present at the 4th Annual Peptide Therapeutics Symposium, November 17 – 18, 2009

SAN DIEGO, CA    September 15, 2009/ NewsWire Today/ — In a talk entitled:  “Non-Invasive Systemic Delivery of Peptides with High Bioavailability”, Dr. Edward Maggio, CEO of Aegis Therapeutics will present recent developments in highly efficient systemic delivery of peptide therapeutics through various transmucosal routes including oral, nasal, and buccal/sublingual administration, at the 4th Annual Peptide […]

Aegis Therapeutics and Albany Medical College Expand Collaboration for Novel Oral Anti-Obesity Drug

SAN DIEGO, CA August 26, 2009 – Aegis Therapeutics and Albany Medical College announced today that they have expanded their existing research relationship, entering into a joint commercialization agreement to promote the clinical development of Albany Medical College’s patented anti-obesity peptide drug.  Under this agreement, Aegis will be responsible for developing an appropriate partnership with […]

Aegis Therapeutics and Phylogica Collaborate to Deliver Phylomer Peptide Drugs with Patient-Friendly Intranasal Sprays

SAN DIEGO, CA – April 14, 2009/MarketWire/– Aegis Therapeutics LLC (“Aegis”) and Australian Drug Discovery company Phylogica Limited (ASX: PYC, “Phylogica”) today announced a collaboration to use Aegis’ proprietary Intravail® transmucosal delivery formulations to deliver Phylogica’s Phylomer® peptide drugs. Phylogica’s CSO and VP of Corporate Development, Dr Paul Watt said: “I am delighted at the […]

New Interferon Formulations Promise to Eliminate Injections in Multiple Sclerosis Treatment

SAN DIEGO, CA Jan. 12, 2009 – Nerveda Inc. and Aegis Therapeutics LLC today announced preclinical results from their joint collaboration aimed at developing non-injectable formulations of the beta-interferons.  The beta interferons, beta-1a (tradename Rebif®), and beta 1b (tradenames Betaseron® and Betaferon®) are closely related injectable protein drugs in the interferon family that are used […]

Aegis Therapeutics’ Intravail® Technology Selected as Winner in Pharmaceutical Technology's “Innovations in Pharma Science Awards” for 2008

SAN DIEGO, CA January 6, 2009/MarketWire/– Aegis Therapeutics LLC’s Intravail® transmucosal absorption enhancement technology has been selected as a winner in Pharmaceutical Technology’s “Innovations in Pharma Science Awards”.  Intravail® excipients make it possible to administer previously injectable-only drugs such as growth hormone, interferon, glucagon, and siRNA drugs through various non-invasive means including metered nasal sprays, […]